曾因“数据乌龙”被礼来退货的产品,成了IL-2先驱的“救命稻草”

药渡
29 Jun

正文共:3153字5图预计阅读时间:10分钟这或许是Nektar Therapeutics“最解气”的时刻。2025年6月24日,Nektar宣布旗下REZPEG(NKTR-358,以下简称358),在用于治疗特应性皮炎(AD)的2b期研究结果报阳。受此消息影响,Nektar股价大涨156%,总市值直接翻了3倍,从1亿美元变为了如今的3亿美元。之所以说“解气”,不是因为股价涨了多少,而是...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10